Performance of the EQ-5D in patients with irritable bowel syndrome

Value in Health

Volumn 9, Issue 2, 2006, Pages 90-97

  Bushnell, Donald M ^a   Martin, Nona L ^a   Ricci, Jean François ^b   Bracco, Andrea ^b  

^a Health Research Associates Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

EQ 5D; Irritable bowel syndrome; Quality of life; Reliability; Validity

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EQ 5D SCALE; FEMALE; HEALTH STATUS; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RATING SCALE; VALIDATION PROCESS; VISUAL ANALOG SCALE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; GERMANY; INSTRUMENTATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REPRODUCIBILITY; SICKNESS IMPACT PROFILE; SPAIN; STATISTICS; UNITED KINGDOM; VALIDATION STUDY;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; GREAT BRITAIN; HEALTH STATUS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SATISFACTION; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; SPAIN;

EID: 33646444912     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00086.x     Document Type: Article

References (36)

1. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:3-15.
2. Talley NJ. Pharmacologic therapy for irritable bowel syndrome. Am J Gastroenterol 2003;98:750-8.
3. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31.
4. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome, an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643-50.
5. Hahn BA, Yan S, Strassel S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999;60:77-81.
6. Olden KW. Approach to the patient with severe refractory irritable bowel syndrome. Curr Treat Options Gastroenterol 2003;6:311-17.
7. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001;19:643-53.
8. Kellow JE. Treatment goals in irritable bowel syndrome. Int J Clin Pract 2001;55:546-51.
9. Thompson WG, Hungin AP, Neri M, et al. The management of irritable bowel syndrome: a European, primary and secondary care collaboration. Eur J Gastroenterol Hepatol 2001;13:933-9.
10. Borum ML. Irritable bowel syndrome. Gastroenterology 2001;28:523-38.
11. Zaman A. Irritable bowel syndrome. Clin Cornerstone 2002;4:22-32.
12. Drossman DA, Whitehead WE, Camilleri M, for the Patient Care Committee American Gastroenterology Association. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997;112:2120-37.
13. Camilleri M. Management of irritable bowel syndrome. Gastroenterology 2001;120:652-68.
14. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003;56:362-9.
15. Fennerty MB. Traditional therapies for irritable bowel syndrome: an evidence-based appraisal. Rev Gastroenterol Disord 2003;3(Suppl. 2):S18-24.
16. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-47.
17. Kind P. The EuroQol instrument, an index of health-related quality of life. In: Spilker B, ed., Quality of Life and Pharmacoeconomics in Clinical Trials (2nd ed.). Philadelphia, PA: Lippincott-Raven Publishers, 1996.
18. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
19. The EuroQoL database. Available from: http://www.euroqol.org. [Accessed October 5, 2005].
20. Weinstein MC, Siegel JE, Gold MR, et al. Recommendation of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
21. Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002;20:455-62.
22. Drossman DA, Richter JE, Talley NJ, eds. et al. The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment (1st ed.). McLean, VA: Degnon Associates, 1994.
23. Ricci JF, Walters S, Ward S, Akehurst R. Quality of life of IBS patients in the United Kingdom compared with a general population sample. Gastroenterology 2003;123:A518.
24. Badia X, Mearin F, Caballero A, et al. Economic burden of irritable bowel syndrome (IBS): one year results. RITMO study. Value Health 2003;6:684.
25. Drossman DA, ed. Rome II: The Functional Gastrointestinal Disorders - Diagnosis, Pathophysiology, and Treatment: a Multinational Consensus (2nd ed.). McLean, VA: Degnon Associates, 2000.
26. Grüger J, Schultes HJ, Pirk O, van Assche D. The utility benefits of tegaserod in irritable bowel syndrome. Gut 2001;49(Suppl. III):A3001.
27. Kind P. Guidelines for value sets in economic and non-economic studies using EQ-5D. In: Brooks R, Rabin R, de Charro F, eds., The Measurement and Valuation of Health States Using EQ-5D: A European Perspective. Dordrecht: Kluwer Academic Publishers, 2003; 29-41.
28. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.
29. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
30. Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43:400-11.
31. Drossman DA, Patrick DL, Whitehead WE, et al. Further Validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999-1007.
32. SPSS, Inc. Statistical Package for the Social Sciences Base 10.0 User's Guide. Chicago, IL: SPSS, Inc., 1999.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences (Revised Edition). New York: Academic Press, 1997.
34. Fayers PM, Machin D. Quality of Life: Assessment, Analysis and Interpretation. Chichester: John Wiley & Sons, 2000.
35. Granlek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60.
36. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQoL: Results from UK General Population Survey. CHE Discussion Paper 138. York: Centre for Health Economics, University of York (UK), 1997.